The Role of Socioeconomic Factors Contributed to The Prevalence of Children under Five Years Old with Small Stature in Jatinangor

Background: Indonesia  is on the fifth in world population for children with small stature. It could affect to their future, so growth disorders should be detected as early as possible. The influence of growth disorders is inseparable from the socioeconomic condition of the family.  This study aims to analyze the influence of socioeconomic based on education, occupation and family income towards small stature children under five years old in Jatinangor.Methods: This was a study of analytic cross sectional with multi-stage proportionate consecutive sampling. 110 samples of children under five years of age (12–59months) from 12 villages (6087 children) in Jatinangor sub district were taken on October and November 2012. Their height was measured using a microtoise based on WHO Growth Chart and the socioeconomic status was measured using questionnaire completed by their motherResults: There were 32 children (29,1%) with small stature. The relationship between maternal education with short stature (p=0.310), father’s education with small stature (p=0.368), mother’s occupation with small stature (p=0.774), father’s occupation with small stature (p=0.524) and family income with small stature (p=0.890) after it was examined using chi-squre test were not significant (p>0.05).Conclusion: In Jatinangor, there are still many children with small stature under five years old and the socioeconomic factors do not have any relationship with this condition. [AMJ.2015;2(1):298–303

Safety and Preliminary Immunogenicity of Recombinant Hepatitis B (Bio Farma) Vaccine in Adults and Children: A Phase 1 Clinical Trial

Background: In order to fulfil the requirements of the national immunization program and sustain the production capacity of the monovalent Hepatitis B vaccine, this study aimed to assess the safety and immunogenicity of the recombinant Hepatitis B Vaccine (Bio Farma) using the new Hepatitis B bulk. Methods: This study was an experimental, randomized, double-blinded, and controlled Phase I clinical trial, with 100 healthy subjects divided into 50 adults and 50 adolescents. Subjects were randomly assigned to receive either the Bio Farma registered Recombinant Hepatitis B Vaccine (group A) or a new source of Hepatitis B bulk (group B). Subjects received one or three doses of vaccine, depending on the baseline anti-Hbs titer. Subjects were given diary cards to record solicited and unsolicited adverse events for 28 days following vaccination. Vaccine immunogenicity was assessed by measuring the level of HBsAg antibody titer elevation.Results: No serious adverse events were reported during clinical trials. The frequencies of adverse events were not significantly different between the two vaccine-randomized groups. The most immediately observed local reaction was local pain, reported by 35.7–42.8% of adults and 24.0–26.3% of adolescents, without any systemic reactions. Seroconversion in adults in group B reached 100% and 78.5% in group A, meanwhile in adolescent subjects in both groups it reached 100%. A substantial increase in geometric mean titer (GMT) was observed in the majority of subjects after immunization.Conclusion: Recombinant Hepatitis B Vaccine with a new source of HBsAg B bulk is safe, well tolerated, and highly immunogenic

The Role of Socioeconomic Factors Contributed to The Prevalence of Children under Five Years Old with Small Stature in Jatinangor

Background: Indonesia is on the fifth in world population for children with small stature. It could affect to their future, so growth disorders should be detected as early as possible. The influence of growth disorders is inseparable from the socioeconomic condition of the family. This study aims to analyze the influence of socioeconomic based on education, occupation and family income towards small stature children under five years old in Jatinangor. Methods: This was a study of analytic cross sectional with multi-stage proportionate consecutive sampling. 110 samples of children under five years of age (12–59months) from 12 villages (6087 children) in Jatinangor sub district were taken on October and November 2012. Their height was measured using a microtoise based on WHO Growth Chart and the socioeconomic status was measured using questionnaire completed by their mother Results: There were 32 children (29,1%) with small stature. The relationship between maternal education with short stature (p=0.310), father’s education with small stature (p=0.368), mother’s occupation with small stature (p=0.774), father’s occupation with small stature (p=0.524) and family income with small stature (p=0.890) after it was examined using chi-squre test were not significant (p>0.05). Conclusion: In Jatinangor, there are still many children with small stature under five years old and the socioeconomic factors do not have any relationship with this condition

Faktor-Faktor Penentu Vaccine Hesitancy pada Orang Tua Anak Usia 6-12 Tahun terhadap Vaksin COVID-19 di Kabupaten Bandung

Latar belakang. Hingga 18 Mei 2020, 584 anak terkonfirmasi positif COVID-19 di Indonesia, mendorong upaya pencegahan melalui vaksinasi anak. Kendati Ikatan Dokter Anak Indonesia mendukung vaksinasi COVID-19 pada anak usia 6–11 tahun, terdapat keraguan (hesitancy) dan penolakan vaksin yang perlu dipahami faktornya. Tujuan. Penelitian bertujuan mengeksplorasi adanya keraguan terkait vaksinasi COVID-19 pada anak dan menganalisis faktor-faktor yang memengaruhi orang tua. Metode. Penelitian analitik kuantitatif dengan desain potong lintang, menggunakan data sekunder yang diperoleh dari penelitian sebelumnya yang merupakan bagian dari riset Academic Leadership Grant meliputi data demografis subjek penelitian, tingkat pengetahuan subjek penelitian mengenai COVID-19, serta status keraguan subjek penelitian terhadap vaksin COVID-19. Hasil. Didapat 613 subjek penelitian yaitu orang tua yang memiliki setidaknya satu orang anak berusia 6-12 tahun yang memenuhi kriteria inklusi dan tidak memenuhi kriteria eksklusi. Dari 613 subjek, sebagian besar memiliki skor pengetahuan COVID-19 yang baik pada 419 orang (68,4%) dan sebagian besar menunjukkan tanpa keraguan pada 546 (89,1%). Pendidikan terakhir (p=0,002 <0,05) dan riwayat infeksi COVID-19 pada keluarga (p=0,007 <0,05) merupakan faktor yang secara signifikan berpengaruh terhadap skor pengetahuan COVID-19. Kesimpulan. Tingkat pendidikan dan riwayat infeksi COVID-19 pada keluarga merupakan faktor yang signifikan secara statistik terhadap tingkat pengetahuan orangtua anak usia 6-12 tahun mengenai COVID-19. Tidak terdapat faktor yang signifikan secara statistik terhadap vaccine hesitancy pada orangtua anak usia 6-12 tahun

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults.

One of the newest strategies developed by the Global Influenza Strategy has been to broaden the composition of the current influenza vaccine formulations from trivalent products to quadrivalent products. This study aimed to assess the immunogenicity and safety of Quadrivalent Influenza HA vaccine (QIV) compared with Trivalent Influenza HA vaccine (TIV) and to evaluate three consecutive batches of QIV equivalence in Indonesian children and adults. This was an experimental, randomized, double blind, four arm parallel group bridging study involving unprimed healthy children and adults aged 9-40 years. A total of 540 subjects were enrolled in this study and randomized into four arm groups. Each subject received one dose of TIV or QIV with three different batch codes. Serology tests were performed at baseline and 28 days after vaccination. Hemagglutination inhibition (HI) antibody titers were analyzed for Geometric Mean Titer (GMT), seroprotection, and seroconversion rates. Solicited, unsolicited, and serious adverse events were observed up to 28 days after vaccination. A total of 537 subjects completed the study per protocol and were analyzed for immunogenicity criteria. All randomized subjects were analyzed for safety criteria. The percentage of the subjects with anti-HI titer ≥1:40 28 days after QIV vaccination was 99.5% for A/H1N1; 99.5% for A/H3N2; 93.1% for B/Texas, and 99.0% for B/Phuket. The seroprotection, GMT, and seroconversion rates of QIV were not significantly different from those of TIV for the common vaccine strains (p > 0.01) and were significantly different from those of TIV for the added B/Phuket strains (p < 0.01). Most solicited injection-site and systemic reactions with either vaccine were mild to moderate and resolved within a few days. Antibody response to QIV were equivalence among vaccine batches and comparable between age groups for each of the 4 strains. QIV was immunogenic and well-tolerated and had immunogenicity and safety profiles compared with TIV for all common strains. The immunogenicity of the three batches of QIV was equivalent for the four strains. Trial registration. Clinical Trial registration: NCT03336593

Psychometric Properties of the Suicidal Ideation Scale in the Indonesian Language

Introduction: Suicide is one of the leading cause of mortality among adolescents and young adults, especially in low to middle-income countries. Research found that screening for suicidal ideation in non-clinical populations such as schools or communities is an important step toward preventing suicide. Despite so, not all screening tools have the capabilities to accurately detect suicidal ideation among adolescents and young adults in non-clinical populations. The Suicidal Ideation Scale (SIS) is one of the most used questionnaires to measure suicidal thoughts in non-clinical populations. This study aims to investigate the psychometric properties of SIS among adolescents and young adults in Indonesia, especially in non-clinical populations. Methods: After a series of language and cultural adaptations, 1254 senior high school and university students completed the Indonesian version of SIS using 3 standard questionnaires, namely Patient Health Questionnaire-9/PHQ-9, Beck Depression Inventory-II/BDI-II, and Children’s Depression Inventory/CDI. The SIS content validity, internal consistency, test-retest reliability and concurrent, as well as internal structure validity, were investigated using content validity index (CVI), Cronbach’s Alpha, Pearson product-moment correlation, and confirmatory factor analysis (CFA), respectively. Results: The result showed that SIS has good to excellent internal consistency and test-retest reliability. Based on the validity indicators, it has satisfactory content and convergent validity, and further support the one-factor and 2-factor model for factorial validity. Both one-factor and 2 factor model are suitable to use in non-clinical settings. Conclusions: SIS is a valid and reliable tool for suicide ideation screening in adolescents and young adults in non-clinical populations. This validated questionnaire can be used in the early detection of suicidal ideation among adolescents and young adults in non-clinical populations, thus contributing to developing strategies and policies to prevent suicide among Indonesian adolescents and young adults at group and institutional levels

DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18–24 months old

Abstract Background The new combination of DTwP-HB-Hib vaccines has been developed in Indonesia following World Health Organization (WHO) recommendation and integrated into national immunization program. The aims of the study were to measure 1) antibody persistence 12–18 months after a primary series, 2) immune response and safety after a booster dose of DTwP-HB-Hib. Methods This was a multi-center, open-labeled, prospective, interventional study. Subjects who had received complete primary dose of DTwP-HB-Hib vaccine from the previous phase III trial were recruited in this trial. Subjects were given one dose of DTwP-HB-Hib (Pentabio®) booster at age 18–24 months old. Diphtheria, tetanus, pertussis, hepatitis B, Hemophilus influenza type B antibodies were measured before and after booster to determine antibody persistence and immune response. Vaccine adverse events were assessed immediately and monitored until 28 days after the booster recorded with parent’s diary cards. Results There were 396 subjects who completed the study. Increased proportion of seroprotected subjects from pre-booster to post-booster were noted in all vaccine antigens: 74.5 to 99.7% for diphtheria; 100 to 100% for tetanus; 40.4 to 95.5% for pertussis; 90.2 to 99.5% for hepatitis B; and 97.7 to 100% for Hib. Common systemic adverse events (AEs) were irritability (23.7–25%) and fever (39.9–45.2%). Local AEs such as redness, swelling, and induration were significantly less common in the thigh group (7.7, 11.3, and 7.1%) than in the deltoid group (28.9, 30.7, and 25%) (P < 0.001). Most AEs were mild and resolved spontaneously within three-day follow-up period. Conclusions Booster of DTwP-HB-Hib vaccine at age 18–24 months is required to achieve and maintain optimal protective antibody. The vaccine is safe and immunogenic to be used for booster vaccination. Trial registration NCT02095314 (retrospectively registered, March 24, 2014)